Publications

2023

Jalkanen J, Khan S, Elima K, Huttunen T, Wang N, Hollmén M, Elo LL, Jalkanen S. Polymorphism in Interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Critical Care. In press.

Singhal D, Borner K, Chaikof EL, Detmar M, Hollmén M, Iliff J, Itkin M, Makinen T, Oliver G, Padera T, Quardokus E, Radtke AJ, Suami H, Weber GM, Rovira II, Muratoglu SC, Galis ZS. Mapping the Lymphatic System Across Body Scales and Expertise Domains: A Report from the 2021 National Heart, Lung, and Blood Institute Workshop at the Boston Lymphatic Symposium. Frontiers in Physiology. 2023, 14:1099403. doi: 10.3389/fphys.2023.1099403. eCollection 2023.

Koivula T, Lempiäinen S, Rinne P, Hollmén M, Sundberg CJ, Rundqvist H, Minn H, Heinonen IHA. Acute exercise mobilizes CD8 + cytotoxic T cells and NK cells in lymphoma patients. Frontiers in Physiology. 2023,13:1078512. doi: 10.3389/fphys.2022.1078512. eCollection 2022.

2022

Wolf S, Rannikko JH, Virtakoivu R, Cinelli P, Felmerer G, Burger A, Giovanoli P, Detmar M, Lindenblatt N, Hollmén M, Gousopoulos E. A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema. Frontiers in Immunology. 2022 Dec 20;13:1004609. doi: 10.3389/fimmu.2022.1004609. eCollection 2022.  

Monfrini E, Pelucchi S, Hollmén M, Viitala M, Mariani R, Bertola F, Majore S, Di Fonzo A, Piperno A. Biallelic STAB1 pathogenic variants cause hereditary hyperferritinemia. medRxiv 2022.11.24.22282670; doi: https://doi.org/10.1101/2022.11.24.22282670

Hua Y, Vella G, Rambow F, Allen E, Martinez AA, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, Floris G, Laoui D, Hollmén M, Lambrechts D, Merchiers P, Marine J-C, Schlenner S, Bergers G. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell 2022, https://doi.org/10.1016/j.ccell.2022.11.002

Schmauch E, Ojanen J, Galani K, Jalkanen J, Hollmén M, Gunn J, Kiviniemi T, Kaikkonen-Määttä M, Kellis M, Linna-Kuosmanen S. QClus: Robust and reliable preprocessing method for human heart snRNA-seq. BioRxiv, doi: https://doi.org/10.1101/2022.10.21.513315

Moisio O, Virta J, Yatkin E, Liljenbäck H, Palani S, Viitanen R, Miner M, Oikonen V, Tolvanen T, Vugts D, Taimen P, Li X-G, Hollmén M, Jalkanen S, Roivainen A. Preclinical Evaluation of a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, 89Zr-Desferrioxamine-Bexmarilimab, in a Rabbit Model of Renal Fibrosis. The Journal of Nuclear Medicine. 2022 Oct 27;jnumed.122.26472.

Koskinen A, Aittokallio J, Gunn J, Relander A, Viikinkoski E, Vasankari T, Jalkanen J, Hollmén M, Kiviniemi T. Disadvantages of High Fluid Infusion Rate in Cardiac Surgery. EJA 2022, 39(12):963-966.

Mutka M, Virtakoivu R, Joensuu K, Hollmén M, Heikkilä P. Clever-1 positive macrophages in breast cancer. Breast Cancer Res Treat 2022 Aug 2. doi: 10.1007/s10549-022-06683-4

Spourquet C, Delcorte O, Lemoine P, Dauguet N, Loriot A, Achouri Y, Hollmén M, Jalkanen S, Huaux F, Lucas S, Van Meerbeeck P, Knauf JA, Fagin JA, Dessy C, Mourad M, Marbaix E, Henriet P, Tyteca D, Pierreux CE. BRAF^V600E expression in thyrocytes causes rapid recruitment of immunosuppressive STABILIN-1 macrophages. Cancers 2022 14(19), 4687.

Lee MH, Laajala E, Kreutzman A, Järvinen P, Nisen H, Mirtti T, Hollmén M, Mustjoki M. The tumor and plasma cytokine profiles of renal cell carcinoma patients. Scientific Reports 2022, 12:13416.

Hollmén M, Maksimow M, Rannikko JH, Karvonen MK, Vainio M, Jalkanen S, Jalkanen M, Mandelin J. Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers. Mol Cancer Ther 2022, 21:1207-1218. https://doi.org/10.1158/1535-7163.MCT-21-0840

2021

Kadiri JJ, Tadayon S, Thapa K, Suominen A, Hollmén M, Rinne P. Melanocortin 1 Receptor Deficiency in Hematopoietic Cells Promotes Expansion of Inflammatory Leukocytes in Atherosclerotic Mice. Front. Immunol., 19 November 2021 | https://doi.org/10.3389/fimmu.2021.774013 

Viikinkoski E, Jalkanen J, Gunn J, Vasankari T, Lehto J, Valtonen M, Biancari F, Jalkanen S, Airaksinen J, Hollmén M, Kiviniemi TO. Red blood cell transfusion induces abnormal HIF-1α response to cytokine storm after adult cardiac surgery. Scientific Reports 2021 Nov 15;11(1):22230. doi: 10.1038/s41598-021-01695-4.

Iftakhar-e-Khuda I, Pessia A, Zheng S, Kankainen M, Kontro M, Karikoski M, Laurila J, Gerke H, Tadayon S, Hollmén M, Tang J, Imhof BA, Salmi M,  Jalkanen S. Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation. Cellular and Molecular Life Sciences 2021, 01 November https://doi.org/10.1007/s00018-021-03977-6

Linna-Kuosmanen S, Schmauch E, Galani K, Boix CA, Hou L, Örd, Toropainen A, Stolze LK, Meibalan E, Mantero JC, Renfro A, Ojanen J, Agudelo LZ, Hollmén M, Jalkanen J, Gunn J, Tavi P, Romanoski CE, MacRae CA, Kaikkonen MU, Garcia-Cardena G, Kiviniemi T, Kellis M. Single-cell dissection of live human hearts in ischemic heart disease and heart failure reveals cell-type-specific driver genes and pathways. bioRxiv 2021.06.23.449672; doi: https://doi.org/10.1101/2021.06.23.449672

Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge M, Robbrecht D, Ma YT, Skyttä T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmén M. Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial. Clin Can Res. 2021, 27:4205–20. DOI: 10.1158/1078-0432.CCR-20-4862

Niittynen DM, Liikamaa L, Jalkanen J, Jalkanen S, Savunen T, Gunn J, Anttila V, Virtanen L, Taimen P, MD, Hollmén M, Pan E, Saura E, Malmberg M. Intravenous Interferon-β1a for the Treatment of Ischemia-Reperfusion Injury in Acute Myocardial Infarct in Pigs. The Heart Surgery Forum 2021-363924 (2)

Keemu H, Vaura F, Maksimow A, Maksimow M, Jokela A, Hollmén M, Mäkelä K. Novel Biomarkers for Diagnosing Periprosthetic Joint Infection from Synovial Fluid and Serum. JBJS 2021; 6 (2) – e20.00067.

Wolf S, Deuel JW, Hollmén M, Felmerer G, Kim B-S, Vasella M, Grünherz L, Giovanoli P, Lindenblatt N, Gousopoulos E. A distinct cytokine profile and stromal vascular fraction metabolic status without significant changes in the lipid composition characterizes lipedema. International Journal of Molecular Sciences. 2021; 22(7), 3313.

Tadayon S, Dunkel J, Takeda A, Eichin D, Virtakoivu R, Elima K, Jalkanen S, Hollmén M. Lymphatic endothelial cell activation and dendritic cell transmigration are modified by genetic deletion of Clever-1. Front. Immunol 2021. doi:10.3389/fimmu.2021.602122

Toivonen R, Vanhatalo S, Hollmén M, Munukka E, Keskitalo A, Pietilä S, Elo L, Huovinen P, Jalkanen S, Pekkala S. Vascular Adhesion Protein 1 Mediates Gut Microbial Flagellin-Induced Inflammation, Leukocyte Infiltration and Hepatic Steatosis. Sci 2021 3(1). https://doi.org/10.3390/sci3010013

2020

Hollmén M, Figueiredo CR, Jalkanen S. New tools to prevent cancer growth and spread: a ‘Clever’ approach. BJC. 2020 Jun 29. doi: 10.1038/s41416-020-0953-0.

Felmerer G, Stylianaki A, Hollmén M, Ströbel P, Stepniewski A, Wang A, Frueh SF, Kim B-S, Giovanoli P, Lindenblatt N, Gousopoulos E. Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. Scientific Reports. 2020 Jul 2;10(1):10947. doi: 10.1038/s41598-020-67987-3.

Jalkanen J, Hollmén M, Jalkanen S. Interferon beta-1a for COVID-19: critical importance of the administration route. Critical Care. 2020 Jun 12;24(1):335. doi: 10.1186/s13054-020-03048-5.

Jalkanen J, Pettilä V, Huttunen T, Hollmén M, Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and upregulation of CD73 in human lung. Intensive Care Med. 2020 May 19. doi: 10.1007/s00134-020-06086-3.

Felmerer G, Stylianaki A, Hägerling R, Wang A, Ströbel P, Hollmén M, Lindenblatt N, Gousopoulos E. Adipose tissue hypertrophy, an aberrant biochemical profile and distinct gene expression in lipedema. J Surg Res. 2020 May 11;253:294-303. doi: 10.1016/j.jss.2020.03.055

2019

Hollmén M, Zheng W, Pollard JW. Editorial: Targeting Myeloid Cells to Fight Cancer. Front Immunol. 2019 Dec 3;10:2835. doi: 10.3389/fimmu.2019.02835.

Z Ghazizadeh, TO Kiviniemi, S Olafsson, D Plotnick, M Beerens, K Zhang, L Gillon, M Steinbaugh, V Barrera, S Ho Sui, AA Werdich, S Kapur, A Eranti, J Gunn, J Jalkanen, J Airaksinen, AG Kleber, M Hollmén, CA MacRae. A Metastable Atrial State Underlies The Primary Genetic Substrate for MYL4 Mutation-Associated Atrial Fibrillation. Circulation, 16 Nov 2019, https://doi.org/10.1161/CIRCULATIONAHA.119.044268

A Takeda, M Hollmén, D Dermadi, J Pan, KF Brulois, R Kaukonen, T Lönnberg, P Boström, I Koskivuo, H Irjala, M Miyasaka, M Salmi, EC Butcher, S Jalkanen. Single-cell survey of human lymphatics unveils marked endothelial cell heterogeneity and mechanisms of homing for neutrophils. Immunity. 2019 17;51(3):561-572.e5. doi: 10.1016/j.immuni.2019.06.027.

S Tadayon, J Dunkel, A Takeda, O Halle, M Karikoski, H Gerke, P Rantakari, R Virtakoivu, O Pabst, M Salmi, M Hollmén*, S Jalkanen*. Clever-1 contributes to lymphocyte entry into the spleen via the red pulp. Science Immunology. 2019 Vol. 4, Issue 33, eaat0297. DOI: 10.1126/sciimmunol.aat0297. *equal contribution

M Viitala, R Virtakoivu, S Tadayon, J Rannikko, S Jalkanen, M Hollmén. Immunotherapeutic Blockage of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors. Clin Can Res. 2019 25(11):3289-3303. doi: 10.1158/1078-0432.CCR-18-3016.

2018

J Jalkanen, M Hollmén, M Maksimow, S Jalkanen, H Hakovirta. Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine 2018 Nov 13. pii: S1043-4666(18)30413-7.

J Dunkel, M Viitala, M Karikoski, P Rantakari, R Virtakoivu, K Elima, M Hollmén, Sirpa Jalkanen, Marko Salmi. Enhanced Antibody Production in Clever-1/Stabilin-1–deficient mice. Front. Immunol. 2018 Oct 8;9:2257.

E Munukka, J Ahtiainen, P Puigbo, S Jalkanen, K Pahkala, A Rintala, UM Kujala, M Hollmén, P Huovinen, G D’Auria, S Pekkala. Six-week endurance exercise alters gut metagenome that is not reflected in systemic metabolism in over-weight women. Front. Microbiol. 2018 Oct 3;9:2323 | https://doi.org/10.3389/fmicb.2018.02323

A Keskitalo, E Munukka, R Toivonen, M Hollmén, H Kainulainen, P Huovinen, S Jalkanen, S Pekkala. Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat fed mice. PLoS ONE 2018, 30;13(5):e0198262. Doi: 10.1371/journal .pone.0198262.

P Rinne, JJ Kadiri, M Velasco-Delgado, S Nuutinen, M Viitala, M Hollmén, M Rami, E Savontaus, S Steffens. Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E-/- Mice. Arteriosclerosis, Trombosis and Vascular Biology, 2018, Feb 38(2):313-323. doi: 10.1161/ATVBAHA.

2017

J Cui, M Hollmén, Li Lina, Y Chen, S Proulx, D Reker, G Schneider, M Detmar. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate. Oncotarget, 2017 Jan 3;8(1):1007-1022. doi: 10.18632/oncotarget.13537.

J Jalkanen, M Hollmén, Sirpa Jalkanen, H Hakovirta. Regulation of CD73 in the Development of Lower Limb Atherosclerosis. Purinergic Signalling, 2017 Mar;13(1):127-134. doi: 10.1007/s11302-016-9545-0.

2016

S Vaara, M Hollmén, A-M Korhonen, M Maksimow, T Ala-Kokko, M Salmi, S Jalkanen, V Pettilä, The FINNAKI Study Group. Soluble CD73 in critically ill septic patients – data from the prospective FINNAKI study. PLoS ONE, 2016 Oct 12;11(10):e0164420. doi: 10.1371/journal.pone.0164420.

J Jalkanen, M Maksimow, M Hollmén, S Jalkanen, H Hakovirta. Compared to Intermittant Claudication Critical Limb Ischemia is Associated with Elevated Levels of Cytokines. PLoS ONE, 2016 Sep 9;11(9):e0162353. doi: 10.1371/journal.pone.0162353.

S Karaman, M Hollmén, S-Y Yoon, HF Alkan, K Alitalo, C Wolfrum, M Detmar. Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice. Scientific Reports, 2016 Aug 11;6:31566. doi: 10.1038/srep31566.

AJ Christiansen, LC Dieterich, I Ohs, S Bachmann, R Bianchi, ST Proulx M Hollmén, D Aebischer, M Detmar. Lymphatic endothelial cells attenuate inflammation via suppression of dendritic cell maturation. Oncotarget 2016 Jun 5. doi: 10.18632/oncotarget.9820.

F Roudnicky, M Hollmén. Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics data 2016, 8;1–3 doi:10.1016/j.gdata.2016.02.009 

2015 

M Hollmén, S Karaman, S Schwager, A Lisibach, AJ Christiansen, M Maksimow, Z Varga, S Jalkanen and M Detmar. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology 11/2015, doi: 10.1080/2162402X.2015.1115177.

Li X, Martinez-Lozano Sinues P, Dallmann R, Bregy L, Hollmén M, Proulx S, Brown SA, Detmar M, Kohler M and Zenobi R. Drug Pharmacokinetics Determined by Real-Time Analysis of Mouse Breath. Angew Chem Int Ed Engl 2015, 4(27):7815-8. doi: 10.1002/anie.201503312. 

M Hollmén, F Roudnicky, S Karaman and M Detmar. Characterization of macrophage – cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports 3/2015 doi:10.1038/srep09188.

J Jalkanen, GG Yegutkin, M Hollmén, K Aalto, T Kiviniemi, V Salomaa, S Jalkanen, H Hakovirta. Aberrant Circulating Levels of Purinergic Signaling Markers are Associated with Several Key Aspects of Peripheral Atherosclerosis and Thrombosis. Circulation Research 2/2015 doi: 10.1161/CIRCRESAHA.116.305715.

2014

S Karaman, M Hollmén, MR Robciuc, A Alitalo, H Nurmi, B Morf, D Buschle, HF Alkan, AM Ochsenbein, K Alitalo, C Wolfrum and M Detmar. Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. Molecular Metabolism 12/2014; doi: 10.1016/j.molmet.2014.11.006.

GG Yegutkin, K Auvinen, P Rantakari, M Hollmén, M Karikoski, R Grénman, K Elima, S Jalkanen and M Salmi. Ecto-5′-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature.. Eur J Immunol 7/2014 doi: 10.1002/eji.201444856.

M Karikoski, F Marttila-Ichihara, K Elima, P Rantakari, M Hollmén, T Kelkka, H Gerke, V Huovinen, H Irjala, R Holmdahl, M Salmi and S Jalkanen. Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. Clin Can Res 10/2014 doi: 10.1158/1078-0432.CCR-14-1236.

He JJ, Martinez-Lozano Sinues P, Hollmén M, Li X, Detmar M and Zenobi R.  Fingerprinting Breast Cancer vs. Normal Mammary Cells by Mass Spectrometric Analysis of Volatiles. Scientific Reports 2014, 4:5196.

2013

N Valtcheva, A Primorac, G Jurisic, M Hollmén and M Detmar. The orphan adhesion G protein coupled receptor GPR97 regulates migration of lymphatic endothelial cells via the small GTPases RhoA and Cdc42. J Biol Chem 2013, 288:35736-48.

2012

M Hollmén, P Liu, K Kurppa, H Wildiers, I Reinvall, T Vahlberg, T van Dorpe, A Smeets, K Deraedt, H Joensuu, D Leahy, P Schöffski and K Elenius. Proteolytic processing of ErbB4 in breast cancer. PLoS ONE 2012, 7(6): e39413.

2005-2010

M Hollmén and K Elenius. Potential of ErbB4 antibodies for cancer therapy. Future Oncology 2010, 6:37-53, Review.

K Peltola, M Hollmén, S-M Maula, E Rainio, R Ristamäki, M Luukkaa, J Sandholm, M Sundvall, K Elenius, PJ Koskinen, R Grenman and S Jalkanen. Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 2009, 11:629-36.

M Hollmén, J Määttä, L Bald, MX Sliwkowski and K Elenius. Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene 2009, 28:1309-19. *patent

D Tvorogov, M Sundvall, K Kurppa, M Hollmén, S Repo, M Johnsson and K Elenius. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009, 284:5582-91.

Tanner M, Hollmén M, Junttila TT, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K and Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis, and sensitivity to trastuzumab. Annals of Oncology 2005, 16:273-278.